Aytu BioScience Company Insiders
| AYTU Stock | USD 2.66 0.10 3.62% |
Aytu BioScience employs about 82 people. The company is managed by 11 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 7.45 employees per reported executive. Breaking down Aytu BioScience's management performance can provide insight into the firm performance.
| Joshua Disbrow CEO CEO, Director |
Aytu BioScience Management Team Effectiveness
Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of Aytu BioScience is $28.12 Million. 30% of Aytu BioScience outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Aytu BioScience Workforce Comparison
Aytu BioScience is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,168. Aytu BioScience holds roughly 82.0 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11. Aytu BioScience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aytu BioScience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aytu BioScience Notable Stakeholders
An Aytu BioScience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aytu BioScience often face trade-offs trying to please all of them. Aytu BioScience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aytu BioScience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Disbrow | CEO, Director | Profile | |
| Mark CPA | Secretary CFO | Profile | |
| Jarrett Disbrow | COO, Director | Profile | |
| Russ McMahen | Senior Development | Profile | |
| Christopher Brooke | Chief Officer | Profile | |
| Margaret Cabano | Vice Operations | Profile | |
| Gerwin Westfield | Senior Affairs | Profile | |
| Topher Brooke | Chief Officer | Profile | |
| Greg Pyszczymuka | Chief Officer | Profile | |
| Ryan CPA | Executive Optimization | Profile | |
| Victoria Cordova | Vice Culture | Profile |
About Aytu BioScience Management Performance
The success or failure of an entity such as Aytu BioScience often depends on how effective the management is. Aytu BioScience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aytu management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aytu management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people.
Please note, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Check Aytu BioScience's Beneish M Score to see the likelihood of Aytu BioScience's management manipulating its earnings.
Aytu BioScience Workforce Analysis
Traditionally, organizations such as Aytu BioScience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aytu BioScience within its industry.Aytu BioScience Manpower Efficiency
Return on Aytu BioScience Manpower
| Revenue Per Employee | 809.5K | |
| Revenue Per Executive | 6M | |
| Net Loss Per Employee | 165.4K | |
| Net Loss Per Executive | 1.2M | |
| Working Capital Per Employee | 196.5K | |
| Working Capital Per Executive | 1.5M |
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.